Abstract
Osteonecrosis of the femoral head is a rare orthopedic disease in children worldwide. Due to the complexity of the disease itself, it causes great harm to children, families, and society. Among them, the morbidity of hip pain caused by osteonecrosis of the femoral head in children seriously affects the patients’ abilities to walk and self-care, thereby causing harm to the patients’ body and mind. As a result, it is crucial to explore drugs for treating pain caused by osteonecrosis of the femoral head in children. In this study, an indomethacinbased anti-inflammatory and analgesic nanodrug (CS/IND NPs) was successfully developed and used for clinical treatment of pain to validate its efficacy. The data demonstrated that in comparison with the pain score (VAS) before treatment, there was a significant difference in subsequent VAS (P <0.05). The hip pain and expression of inflammatory mediators were significantly reduced. However, few adverse reactions were caused by this drug, which can significantly improve the quality of life for patients and are worth of further studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
